Disparities Seen for Central Catheter-Associated Bloodstream Infection
THURSDAY, June 1, 2023 (HealthDay News) -- Central catheter-associated bloodstream infection (CLABSI) rates are higher for Black pediatric patients and patients who speak a language other than English (LOE), according to a study published online May 30 in JAMA Pediatrics.
Caitlin L. McGrath, M.D., from University of Washington in Seattle, and colleagues examined disparities in first CLABSI rates for pediatric patients of minoritized racial, ethnic, and language groups and subsequent outcomes after quality improvement initiatives. The analysis included outcomes of 8,269 hospitalized patients with central catheters (Oct. 1, 2012, to Sept. 30, 2019) at a freestanding quaternary care children's hospital.
The researchers found that the unadjusted infection rates were higher for Black patients (2.8 per 1,000 central catheter days) and patients who spoke an LOE (2.1 per 1,000 central catheter days) versus the overall population (1.5 per 1,000 central catheter days). Overall, 3.4 percent experienced a CLABSI (mean age, 1.34 years; female, 43.3 percent). When adjusting for other factors, higher risk was seen for Black patients (adjusted hazard ratio, 1.8) and patients who spoke an LOE (adjusted hazard ratio, 1.6). Infection rates in both subgroups showed statistically significant changes following quality improvement interventions (Black patients, −1.77; patients speaking an LOE, −1.25).
"These findings suggest that assessing hospital quality metrics for disparities can be an indicator of racism and bias and that targeted interventions to improve equitable care with a specific focus on health care-associated infections may be feasible," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Nasal Colonization With Staph Bacteria Linked to Acute Radiation Dermatitis
FRIDAY, May 12, 2023 (HealthDay News) -- Nasal colonization with Staphylococcus...
Los hombres son más propensos al cáncer que las mujeres, pero ¿por qué?
MIÉRCOLES, 10 de agosto de 2022 (HealthDay News) -- Los hombres son más...
Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 (HealthDay News) -- Cabozantinib plus nivolumab and...